I-123 LABELING AND EVALUATION OF RO-43-0463, A SPET TRACER FOR MAO-B IMAGING

被引:7
作者
BEER, HF [1 ]
ROSSETTI, I [1 ]
FREY, LD [1 ]
HASLER, PH [1 ]
SCHUBIGER, PA [1 ]
机构
[1] KANTONSSPITAL AARAU, DEPT NUCL MED, CH-5000 AARAU, SWITZERLAND
关键词
D O I
10.1016/0969-8051(95)00041-U
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Using the copper assisted halogen exchange the MAO-B inhibitor Po 43-0463, N-(2-aminoethyl)-5-iodo-2-pyridinecarboxamide, was labelled with I-123 as well as with I-125 to allow in vitro and in vivo investigations including SPET with healthy volunteers. Ro 43-0463 is known to inhibit reversibly and specifically MAO-B, having an Ic,, of 3 x 10(-8) Mol/L. The labeling in the presence of CuSO4, and ascorbic acid was optimised, varying time (30 to 105 min), precursor concentration (1-3.5 mg) and temperature (130-200 degrees C). The labeling yield ranged between 60 and 70%. Purification was achieved with Lichrosorb RP-18 (5 mu m, 250 x 8 mm) and 1.5 mL/min 0.36 M H3PO4/EtOH 97/3 [0.01 M (NH4)(2)HPO4]. After neutralisation and sterile filtration the final activity concentration ranged between 18.5 and 37 MBq/mL. Biodistribution studies showed a brain to blood ratio greater than 1 within 1 h p.i. The main radiation burden calculated from these animal data is to alimentary and excretory organs and the ovaries. Autoradiography was performed using rat brain slices and 5 nM [I-125]Ro 43-0463 in TRIS-buffer pH 7.4 for 90 min at 20 degrees C. Its radioactivity pattern corresponds to the known distribution of MAO-B in the rat brain. By displacement with L-deprenyl the highly specific binding of Po 43-0463 was proven in vitro. SPECT studies with normal volunteers corresponded with the pattern found in autoradiography.
引用
收藏
页码:929 / 936
页数:8
相关论文
共 27 条
[1]  
BEER HF, 1992, APPL RADIAT ISOTOPES, V43, P781
[2]   [I-123/I-125]-RO-43-0463, A SITE-SPECIFIC TRACER FOR MAO-B MAPPING WITH AUTORADIOGRAPHY AS WELL AS WITH SPET [J].
BEER, HF ;
FREY, LD ;
ROSSETTI, I ;
REMY, N ;
MAIER, A ;
SCHUBIGER, PA .
JOURNAL OF RECEPTOR AND SIGNAL TRANSDUCTION RESEARCH, 1995, 15 (1-4) :581-593
[3]  
BEER HF, IN PRESS NUCL MED BI
[4]  
BEER HF, IN PRESS J LAB COMPD
[5]   MEASUREMENT OF HUMAN CEREBRAL MONOAMINE-OXIDASE TYPE-B (MAO-B) ACTIVITY WITH POSITRON EMISSION TOMOGRAPHY (PET) - A DOSE RANGING STUDY WITH THE REVERSIBLE INHIBITOR RO-19-6327 [J].
BENCH, CJ ;
PRICE, GW ;
LAMMERTSMA, AA ;
CREMER, JC ;
LUTHRA, SK ;
TURTON, D ;
DOLAN, RJ ;
KETTLER, R ;
DINGEMANSE, J ;
DAPRADA, M ;
BIZIERE, K ;
MCCLELLAND, GR ;
JAMIESON, VL ;
WOOD, ND ;
FRACKOWIAK, RSJ .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 40 (02) :169-173
[6]   MONOAMINE-OXIDASE, BRAIN AGING AND DEGENERATIVE DISEASES [J].
BENEDETTI, MS ;
DOSTERT, P .
BIOCHEMICAL PHARMACOLOGY, 1989, 38 (04) :555-561
[7]  
BERMAN DS, 1975, J NUCL MED, V16, P865
[8]   [H-3] RO-19-6327 - A REVERSIBLE LIGAND AND AFFINITY LABELING PROBE FOR MONOAMINE OXIDASE-B [J].
CESURA, AM ;
GALVA, MD ;
IMHOF, R ;
KYBURZ, E ;
PICOTTI, GB ;
DAPRADA, M .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1989, 162 (03) :457-465
[9]  
DAPRADA M, 1988, PROGR CATECHOLAMIN B, P359
[10]   MONOAMINE OXIDASE-B (MAO-B) INHIBITOR THERAPY IN PARKINSONS-DISEASE - THE DEGREE AND REVERSIBILITY OF HUMAN BRAIN MAO-B INHIBITION BY RO 19 6327 [J].
FOWLER, JS ;
VOLKOW, ND ;
LOGAN, J ;
SCHLYER, DJ ;
MACGREGOR, RR ;
WANG, GJ ;
WOLF, AP ;
PAPPAS, N ;
ALEXOFF, D ;
SHEA, C ;
GATLEY, SJ ;
DORFLINGER, E ;
YOO, K ;
MORAWSKY, L ;
FAZZINI, E .
NEUROLOGY, 1993, 43 (10) :1984-1992